The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $6.03 in the prior trading day, Amicus Therapeutics Inc (NASDAQ: FOLD) closed at $6.11, up 1.33%. In other words, the price has increased by $1.33 from its previous closing price. On the day, 2.91 million shares were traded.
Ratios:
Our goal is to gain a better understanding of FOLD by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.51 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 1168.61. For the most recent quarter (mrq), Quick Ratio is recorded 2.47 and its Current Ratio is at 3.34. In the meantime, Its Debt-to-Equity ratio is 2.29 whereas as Long-Term Debt/Eq ratio is at 2.25.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Morgan Stanley on December 13, 2024, Downgraded its rating to Equal-Weight and sets its target price to $12 from $17 previously.
On May 30, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $18.Wells Fargo initiated its Overweight rating on May 30, 2024, with a $18 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 19 ’25 when Campbell Bradley L sold 400 shares for $10.00 per share. The transaction valued at 4,000 led to the insider holds 1,150,657 shares of the business.
BRADLEY CAMPBELL bought 400 shares of FOLD for $3,940 on Feb 19 ’25. On Dec 02 ’24, another insider, Campbell Bradley L, who serves as the President and CEO of the company, sold 7,500 shares for $10.02 each. As a result, the insider received 75,124 and left with 886,654 shares of the company.
Stock Price History:
Over the past 52 weeks, FOLD has reached a high of $12.65, while it has fallen to a 52-week low of $5.81. The 50-Day Moving Average of the stock is -8.06%, while the 200-Day Moving Average is calculated to be -33.92%.
Shares Statistics:
A total of 307.92M shares are outstanding, with a floating share count of 297.28M. Insiders hold about 3.46% of the company’s shares, while institutions hold 99.78% stake in the company.
Earnings Estimates
A comprehensive evaluation of Amicus Therapeutics Inc (FOLD) is underway, with the input of 4.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.11, with high estimates of $0.12 and low estimates of $0.11.
Analysts are recommending an EPS of between $0.36 and $0.28 for the fiscal current year, implying an average EPS of $0.33. EPS for the following year is $0.68, with 5.0 analysts recommending between $0.84 and $0.58.
Revenue Estimates
10 analysts predict $147.04M in revenue for the current quarter. It ranges from a high estimate of $157.6M to a low estimate of $137.77M. As of the current estimate, Amicus Therapeutics Inc’s year-ago sales were $126.67MFor the next quarter, 10 analysts are estimating revenue of $164.1M. There is a high estimate of $168.11M for the next quarter, whereas the lowest estimate is $157.31M.
A total of 12 analysts have provided revenue estimates for FOLD’s current fiscal year. The highest revenue estimate was $633.48M, while the lowest revenue estimate was $617.08M, resulting in an average revenue estimate of $621.78M. In the same quarter a year ago, actual revenue was $528.29MBased on 12 analysts’ estimates, the company’s revenue will be $763.38M in the next fiscal year. The high estimate is $832.6M and the low estimate is $727.4M.
